Cargando…
Adeno-Associated Virus (AAV) Versus Immune Response
Decades ago, Friedmann and Roblin postulated several barriers to gene therapy, including tissue targeting, delivery across the blood–brain barrier (BBB), and host immune responses. These issues remain pertinent till today. Since then, several advances have been made in elucidating structures of aden...
Autores principales: | Rabinowitz, Joseph, Chan, Ying Kai, Samulski, Richard Jude |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409805/ https://www.ncbi.nlm.nih.gov/pubmed/30691064 http://dx.doi.org/10.3390/v11020102 |
Ejemplares similares
-
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Ronzitti, Giuseppe, et al.
Publicado: (2020) -
Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Basner-Tschakarjan, Etiena, et al.
Publicado: (2014) -
Prediction of Adeno-Associated Virus Neutralizing Antibody Activity for Clinical Application
por: Wang, Mei, et al.
Publicado: (2015) -
Adeno‐associated virus (AAV)-based gene therapy for glioblastoma
por: Xu, Xin, et al.
Publicado: (2021) -
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
por: Naso, Michael F., et al.
Publicado: (2017)